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ABSTRACT 
THE EFFECTS OF ANGIOGENIC GROWTH FACTORS ON MESENCHYMAL 
STEM CELL PROLIFERATION AND DIFFERENTIATION 
TO VASCULAR CELL FATES 
by William D'Angelo 
May 2013 
Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into 
several cell lineages, including mural cells, which surround and support blood vessels, 
and possibly endothelial cells, which form the blood vessel walls. In this study, we 
investigated the effects of basic fibroblast growth factor (bFGF) and vascular endothelial 
growth factor (VEGF), two of the best-characterized angiogenic factors, on MSC 
proliferation and differentiation. We hypothesized that treatment with these two factors 
could inhibit mural cell character and promote differentiation toward an endothelial cell 
fate. C3H/10Tl/2 cells (a line of MSCs derived from mouse embryonic tissues) were 
treated with bFGF and VEGF, either alone or in combination, over a 9-day course. The 
effects on cell proliferation and cell type-specific marker expression were determined by 
cell cycle analysis, quantitative real-time PCR (RT-qPCR) analysis, and flow cytometry. 
bFGF significantly stimulated MSC proliferation and inhibited expression of mural cell 
markers, with no apparent effect on endothelial marker expression. VEGF alone or in 
combination with bFGF had no significant effects on expression of mural cell or 
endothelial cell differentiation markers. We conclude that these angiogenic factors, 
although critical in maintaining the properties of endothelial cells, are not sufficient to 
promote C3H/10Tl/2 cell differentiation to endothelial cells. 
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Vessel Structure 
CHAPTER I 
INTRODUCTION 
Vascular Development 
1 
The mammalian vasculature is an intricate organ that supplies all cells of the body 
with necessary oxygen and nutrients and is able to sense and respond to dynamic tissue 
needs. Blood vessels are composed of three main parts: a layer of endothelial cells that 
makes up the luminal surface of the vessel; a layer of mural cells, which surround the 
vessel and function in regulating vessel diameter to control blood flow, stabilizing 
contacts between endothelial cells, and secretion of extracellular matrix components; and 
a basement membrane, a layer of collagen and other connective tissue proteins that 
provides structural support and participates in signaling with endothelial and mural cells. 
In large vessels, vascular smooth muscle cells (vSMCs) make up the mural cell 
component and are found in a continuous abluminal sheath separated from the vessel 
endothelium by the basement membrane. In capillaries, the microvessels where gas and 
nutrient exchange occurs , the mural cells are pericytes, which are embedded within the 
basement membrane and make focal contacts with multiple endothelial cells. Pericyte 
coverage of capillaries is discontinuous and variable, reportedly ranging between 10% 
and 50% depending on the tissue (Shepro & Morel, 1993). Pericytes are positioned on the 
vessel to minimally inhibit gas and nutrient exchange with the tissue, and their variable 
abundance probably reflects different functional requirements of capillary beds in 
different tissues (Gerhardt & Betsholtz, 2003). 
Vasculogenesis and Angiogenesis 
Vascular development proceeds through two related processes: vasculogenesis, 
the initial, de novo formation of vessels; and angiogenesis, the sprouting of new vessels 
outward from the walls of already-formed vessels. Vasculogenesis occurs mainly during 
embryonic development, when multipotent vascular progenitor cells (hemangioblasts) in 
the yolk-sac differentiate to so-called blood islands containing endothelial and 
hematopoietic precursors. As these precursors differentiate, blood islands coalesce and 
organize into the vessels of the primary vascular plexus. 
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After the primary vascular plexus is formed by vasculogenesis, further vascular 
development proceeds via the process of angiogenesis, as new vessels sprout and grow to 
fill out the primitive vasculature, which is then subjected to pruning and remodeling. 
Unlike vasculogenesis, angiogenesis continues to some extent into adulthood, for 
instance during wound healing. Sprouting angiogenesis occurs when a growth factor 
signal (for example, vascular endothelial growth factor, VEGF) activates endothelial cells 
of an existing vessel wall, as illustrated in Figure 1. Before the new sprout can form, the 
basement membrane must be degraded to allow an opening for new cells to grow into. 
Activated endothelial cells begin to produce proteases that break down basement 
membrane proteins. If many or all of the endothelial cells in a given area of a vessel 
were to become activated and migratory, the extant vessel would be destroyed, 
interrupting local circulation. So to prevent vessel destruction and disorganized growth, a 
mechanism of lateral inhibition by Notch signaling selects a single endothelial cell to 
adopt the invasive tip cell phenotype and migrate toward the VEGF gradient (Gridley, 
2007). As tip endothelial cells continue to migrate along the growth factor gradient, the 
trailing stalk cells proliferate and form into a tube structure to make the walls of the new 
vessel. The final stage of vessel growth involves the recruitment of mural cells which 
surround the vessel, stabilize contacts between endothelial cells, and secrete a new 
basement membrane to result in a mature vessel. 
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Figure 1. Angiogenic process and proposed role of mesenchymal stem cells. (a) 
Endothelial cells are activated and begin migrating toward a growth factor gradient. (b) 
A specialized tip cell leads the vessel sprout while trailing stalk cells proliferate to form 
new vessel walls. A primitive vascular network is formed (c), followed by recruitment of 
mural cells to stabilize the vessel (d), possibly differentiated from mesenchymal stem 
cells (MSCs). Alternatively, MSCs may differentiate to endothelial cells and incorporate 
directly into the vessel walls (figure adapted from Wood, Kamrn, & Asada, 2011). 
Roles of Mural Cells in the Vasculature 
While endothelial cell behavior has been extensively studied for many years, 
mural cells have received comparatively little attention. However, these cells have 
several important roles in angiogenesis and vessel maintenance and function. Several 
studies have shown that pericyte investment of new vessels is concurrent with vessel 
maturity (von Tell, Armulik, & Betsholtz, 2006) and is apparently necessary for vessel 
stability, as animal models with faulty pericyte recruitment show vessel regression and 
defects in circulation (Hall, 2006). The chronically inflamed, malformed, and leaky 
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vasculature characteristic of tumors is often marked by a decrease in pericyte coverage 
(Hall, 2006), and pericyte loss is one of the early events in diabetic retinopathy (Hammes, 
2005). 
The presence of pericytes is thought to stabilize vessels by several different 
mechanisms. One method of pericyte/endothelium interaction is through paracrine 
signaling. For example, knockout studies have shown that PDGF-B production by 
endothelial cells and PDGFR-P expression by pericytes are required for pericyte 
recruitment to new vessels (Enge et al., 2002), and TGF-P production by vessel-
associated pericytes is thought to induce differentiation of endothelial cells and maintain 
their quiescence (Armulik, Abramsson, & Betsholtz, 2005). The angiopoietin/Tie-2 
signaling loop between pericytes and endothelial cells is also involved in vessel 
maturation and stability, as evidenced by embryonic death due to cardiovascular failure 
in animals where this pathway is inactivated (Suri et al., 1996). 
Direct cell-cell contacts are another important mechanism for proper vessel 
maintenance and function. Peg-and-socket junctions between endothelial cells and 
pericytes are characterized by the presence of the cell-cell adhesion protein N-cadherin. 
Administration of N-cadherin-blocking antibodies results in severe vascular defects 
characterized by inefficient pericyte-endothelial contact, and interestingly, disrupted 
endothelial-endothelial contacts (Gerhardt, Wolburg, & Redies, 2000). It seems that N-
cadherin signaling upregulates endothelial expression VE-cadherin (the major cell 
adhesion molecules between endothelial cells)- thus pericyte-endothelial contacts 
directly promote stable connections between endothelial cells to maintain vessel integrity 
(von Tell et al., 2006). 
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Pericytes also have indirect effects on vascular stability through their secretion of 
basement membrane components. Interactions between endothelial cells and extracellular 
matrix proteins are largely mediated through integrin signaling. Integrins are cell-surface 
receptors that can bind matrix components such as collagens, laminins, and fibronectin. 
Integrins have an intracellular domain that can interact with several signaling proteins in 
the cytoplasm, thus signaling to the cell information about the extracellular environment. 
Because different combinations of integrin a. and p subunits can bind different matrix 
substrates, the sum of the integrin signals that a cell receives allows it to sense its 
surroundings in detail. The importance of these signals in vessel stability and endothelial 
quiescence has been shown in many studies (Stratman & Davis, 2012). 
Angiogenic Factors 
Although many growth factors, cytokines, and other regulatory molecules are 
involved in the regulation of blood vessel formation and maintenance, bFGF and VEGF 
are by far the two best studied growth factors that are pivotal for vasculogenesis and 
angiogenesis. The following sections briefly review their model of action and signaling 
pathways that they activate. 
bFGF Signaling 
Basic fibroblast growth factor (bFGF) or FGF2 is a pleiotropic growth factor 
belonging to the fibroblast growth factor superfamily, which contains 22 members (in 
humans) organized into 7 subfamilies. bFGF was originally isolated from the bovine 
pituitary gland in 1974 and characterized as a potent mitogen for fibroblasts and an 
inducer of angiogenesis in vivo (Ornitz, 2000). The bFGF protein ranges from 18-34 kDa 
depending on the translation start site. High and low molecular weight (HMW and LMW) 
isoforms are reported to localize to different intracellular compartments and may lead to 
different physiological effects (Liao et al. , 2009; Reiland & Rapraeger, 1993; Dow & 
White, 2000). While HMW bFGF is thought to localize mainly to the nucleus, LMW 
bFGF is found in both the cytosol and the nucleus, as well as in the extracellular matrix 
(Liao et al., 2009). 
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There are four high-affinity cell surface FGF receptors (FGFRl-4), which belong 
to the receptor tyrosine kinase (RTK) family. FGF receptors are subject to alternative 
splicing to generate different isoforms, each with different ligand binding specificities, 
expression patterns, and physiological effects. These receptors share the same general 
structure, including two or three extracellular immunoglobulin-like (lg-like) repeat 
domains which determine ligand-binding specificity, an acid box region, a heparin 
binding motif, a single transmembrane domain, and an intracellular split tyrosine kinase 
domain near the C-terminal end (Eswarakumar, Lax, & Schlessinger, 2005). 
Ligand binding induces receptor dimerization and autophosphorylation of seven 
tyrosine residues in the intracellular tyrosine kinase domain, resulting in its activation 
(Vecchione et al., 2007). Signaling pathways activated downstream of the receptor are 
shown in Figure 2. Phosphorylated tyrosine residues of the receptor serve as binding 
sites for downstream signal proteins, including the adapter protein FRS2a, which recruits 
Grb2 and Shp2 via their SH2 domains. The FRS2a/Grb2/Shp2 complex recruits SOS, 
which then activates Ras, leading to downstream activation of the MAPK pathways 
ERKl/2, JNK, and p38. Grb2 can also complex with Gabl , which then recruits PI3K to 
activate the Akt pathway. Phospholipase C-gamma (PLC-y) can also bind to the activated 
FGFR, leading to DAG and IP3 production, intracellular Ca2+ release, and PKC activation 
(Eswarakumar et al., 2005). Activation of these pathways can alter gene expression to 
regulate different cellular events, such as cell proliferation and differentiation. 
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In addition to FGFRs, bFGF is also known to bind heparin and heparan sulfate 
proteoglycans (HSPGs) such as perlecan and syndecan. HSPGs are found on the surface 
of most cells and are major components of the extracellular matrix. Evidence suggests 
that these ECM proteins are essential for efficient receptor activation, as cells that cannot 
produce HSPGs require exogenously added heparin for FGF signaling to occur (Omitz et 
al. , 1992). It is thought that HSPGs facilitate signaling by stabilizing transient binding 
between a single FGF molecule and receptor long enough for receptor dimerization to 
form an active signaling complex (Omitz, 2000). 
Besides their direct role in receptor activation, HSPGs also sequester secreted 
bFGF in the basement membrane by preventing its diffusion and protecting from thermal 
degradation and proteolysis (Omitz, 2000). The presence of bFGF in the basement 
membrane has implications for angiogenesis : as activated endothelial cells secrete 
proteases to degrade the basement membrane, bFGF (as well as other matrix-bound 
growth factors) is released to regulate endothelial cell and mural cell behaviors. 
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Figure 2. Signaling pathways activated by bFGF. Ligand binding is facilitated by 
extracellular heparan sulfate proteoglycans (HSPGs) and induces receptor dimerization, 
autophosphorylation, and the assembly of a functional intracellular signaling complex 
that can activate several downstream signaling pathways, including PLC-y/PKC, 
PI3K/Akt, and the MAPK pathways (figure from Lanner & Rossant, 2010), which 
coordinately regulate different cellular events. 
VEGF Signaling 
Vascular endothelial growth factor (VEGF) is a family of growth factors with 
major roles in angiogenesis. VEGF-A is the best characterized, but five related proteins 
have been identified (VEGF-B, C, D, and E, as well as placenta growth factor, PlGF). 
VEGF-A is a well-characterized inducer of angiogenic sprouting and endothelial cell 
proliferation, migration, and survival (Greenberg, 2008). VEGF-A is crucial for proper 
vasculogenesis; the loss of even a single VEGF-A allele results vascular malformation 
and embryonic death (Carmeliet et al., 1996). Additionally, three transmembrane 
receptor tyrosine kinases (VEGFRl-3) have been described. While VEGF-A binds to 
VEGFR-1 and -2, VEGFR-2 is responsible for most of the angiogenic effects of VEGF 
signaling (Ball, Shuttleworth, & Kielty, 2007). VEGFR-1 may serve as a decoy or sink 
for VEGF-A (Fong, Rossant, Gertsenstein, & Breitman, 2002). 
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VEGF receptors function similarly to other RTKs: ligand binding induces 
receptor dimerization and autophosphorylation of tyrosine residues in the cytoplasmic 
domain, followed by endocytosis of the receptor/ligand complex into a signaling 
endosome (Matsumoto & Mugishima, 2006). The downstream signaling pathways in 
endothelial cells have been well-characterized (Fig. 3). Phosphorylated tyrosines serve as 
binding sites for PLC-y, Grb2, and Shb. PLC-y activation leads to production of DAG 
and IP3, which leads to intracellular Ca2+ release and PKC activation. PKC activation 
leads to activation of the MEKIERK pathway via Raf and stimulates cell proliferation. 
Binding of Grb2 and Shb adapter proteins to activated VEGFRs leads to downstream p38 
and PI3K activation, cytoskeletal reorganization, and migration (Matsumoto & 
Mugishima, 2006). Additionally a complex composed of VEGF-NVEGFR2 with VE-
cadherin, ~-catenin, and PI3K is essential for endothelial cell survival (Carmeliet et al. , 
1999). 
VEGF is produced by cells in response to hypoxia, or low levels of oxygen, via a 
mechanism involving the transcription factor hypoxia-inducible factor-1 (HIF-1). At 
normal oxygen levels, the a subunit of HIF-1 is quickly hydroxylated, which flags it for 
ubiquitination and degradation by the proteasome. But the enzyme that hydroxylates 
HIF-1a cannot function under hypoxic conditions, resulting in increased stability of HIF-
1a, which forms a dimer with the constitutively produced~ subunit and binds to 
promoters of responsive genes, including the VEGF gene, stimulating its transcription 
and leading to angiogenesis (Neufeld, Cohen, Gengrinovitch, & Poltorak, 1999). 
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Figure 3. Signaling pathways activated by VEGF. VEGF binding induces receptor 
dimerization, autophosphorylation, and the assembly of a functional intracellular 
signaling complex that can activate several downstream signaling pathways, including 
PLC-y/PKC, PI3K/Akt, and the MAPK pathways (figure from Sigma-Aldrich, 
http://www.sigmaaldrich.com/life-science/cell-biology/learning-center/pathway-slides-
and/signaling-pathways.html). 
Mesenchymal Stem Cells (MSCs) 
Stem Cells 
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The term, stem cell, is applied to cells with two main characteristics: self-renewal 
and multipotency. Self-renewal refers to a cell's ability to reproduce itself without 
differentiation, while multipotency is the ability to differentiate into multiple cell types 
when induced. There are several different types of cells that fall under the category of 
stem cells, and each type has its own unique properties, such as characteristic 
differentiation capacity, tissue of origin, marker expression profiles, morphology, and cell 
cycle control mechanisms. Stem cells can be classified into two broad types, embryonic 
stem cells and adult stem cells. These categories are briefly discussed below. 
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Embryonic stem cells (ESCs) are cells derived from the inner cell mass (ICM) of 
a blastocyst, an early stage of embryonic development. ESCs are pluripotent, or able to 
differentiate into all cell types from all three germ layers (ectoderm, mesoderm, 
endoderm). The discovery and isolation of ESCs has generated tremendous excitement 
over their potential use in regenerative medicine. However, several barriers to clinical 
implementation remain, including ethical concerns about the destruction of embryos 
during harvest and questions about the purity, tumorigenic potential, and irnmunogenicity 
of ESC-derived cells. For these reasons, the greatest contributions of ESCs to date have 
been in the field of basic research, such as cell and developmental biology (Wobus & 
Boheler, 2005). 
Self-renewing and multipotent cells that are derived from post-blastocyst tissues 
are collectively called adult stem cells. Hematopoietic stem cells, which can differentiate 
into all blood cell types, were the first to be discovered when they were isolated from 
bone marrow aspirates (Till & McCulloch, 1961). Since that time, stem cells have been 
isolated from a wide variety of postnatal tissues, such as the brain, skeletal muscle, 
cardiac muscle, intestine, skin, dental pulp, and fat. It seems that most if not all tissues 
and organs contain rare, relatively undifferentiated progenitor cells that are normally 
quiescent but can differentiate to mature cells of that tissue when induced. For instance, 
neural stem cells give rise to neurons and glial cells in the central nervous system, and 
stem cells in the skin and intestines differentiate to replace epithelial cells that are 
continuously ageing. Additionally, recent findings suggest that some adult stem cells 
have a higher plasticity of differentiation potential than was originally appreciated. For 
example, mesenchymal stem cells have been reported to differentiate into non-
mesodermal lineages such as neurons (mesoderm to ectoderm) (Jiang et al., 2002), and 
neural stem cells have been reported to differentiate to hematopoietic progenitors 
(ectoderm to mesoderm) (B jomson, Rietze, Reynolds, Magli, & V escovi, 1999). 
Mesenchymal Stem Cells 
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Mesenchymal stem cells (MSCs) are multipotent cells that are characterized by 
their ability to differentiate into cells of various mesodermal tissues, such as bone, 
cartilage, and fat. Physiologically, MSCs are thought to serve as a reservoir for the 
replenishment of injured or diseased mesodermal cells (Minguell, Erices, & Conget, 
2010). Other possible roles include maintenance of microenvironment via production of 
growth factors, cytokines, and extracellular maintenance components, and regulation of 
immune cell function (Uccelli, Moretta, & Pistoia, 2008). In vitro, they are easily 
cultured, maintained, and induced to differentiate to several functional phenotypes. For 
these reasons, MSCs have attracted attention for their potential roles in medicine and for 
their utility as tools for development and differentiation studies. 
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Figure 4. Typical differentiation potential of MSCs. The classic differentiation potential 
of MSCs includes chondrocytes, osteocytes, and adipocytes. In addition, MSCs from 
various sources have also been induced to differentiate to myocytes, astrocytes, mural 
cells, fibroblasts, and endothelial cells (figure from Grassel 2007). 
MSCs may not comprise a single homogeneous population, and cells with the 
hallmarks of MSCs have been isolated from different tissues and developmental stages. 
Similar populations have been variously described as fibroblast colony forming units 
(Castro-Malaspina et al. , 1980), mesenchymal stem cells, bone marrow stem cells, 
marrow stromal cells, mesenchymal adult progenitor cells, and marrow-isolated adult 
multilineage inducible cells (Minguell et al., 20 10). 
In vitro, MSCs are plastic-adherent and form proliferative colonies. Cells have a 
fibrob last-like morphology with long thin cytoplasmic processes (Pinney & Emerson, 
1989), and are sensitive to post-confluence inhibition of growth (Reznikoff, Brankow, & 
Heidelberger, 1973). Many profiles of molecular marker expression have been described, 
and it seems not all MSCs display all the markers all the time. However, as part of the 
minimum criteria for MSCs proposed by the Mesenchymal and Tissue Stem Cell 
Committee of the International Society for Cellular Therapy, MSCs should express 
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CD105, CD73, and CD90, and should not express CD45, CD34, CD14, CDllb, CD79a, 
CD19, or HLA-DR (Dominici et al., 2006). MSCs have been classically described as able 
to differentiate to osteoblasts, chondrocytes, and adipocytes (Pinney & Emerson, 1989). 
In addition, some papers report differentiation to smooth muscle/mural cells, skeletal 
muscle, cardiac muscle, endothelial cells, and neural cells (Minguell et al., 2010; Wang, 
et al., 2010; Woodbury, Schwarz, Prockop, & Black, 2000). MSCs are distinct from 
hematopoietic stem cells (HSCs) and thus do not differentiate into blood cells. 
MSC isolation is usually achieved using either the colony-forming unit-fibroblast 
(CFU-f) assay or by fluorescence-activated cell sorting (FACS). First, tissue samples 
(often bone marrow aspirates) are separated using density gradient centrifugation. Cells 
at the plasma-solution interface are collected and then subjected to one of the above 
assays. The CFU-f assay involves plating of the primary cells in a tissue culture dish and 
washing away non-adherent cells to obtain adherent, colony-forming cells with a 
fibroblast-like morphology. These cells typically display accepted MSC markers and tri-
lineage potential (Oswald, 2004). For isolation by FACS, primary cells are incubated 
with fluorophore-tagged antibodies that bind to consensus MSC markers, and then a flow 
cytometer is used to separate cells with the desired marker expression profile. For 
instance, Crisan et al. used this technique to sort CD146+/CD34- CD45- CD56-
perivascular cells from several tissues. The sorted cells showed characteristic MSC 
morphology and differentiation potential (Crisan et al., 2008). 
Differences in tissue source, developmental stage, and reported molecular marker 
expression profile, as well as variation in isolation, culture, and differentiation protocols, 
have led to ambiguity about the in vivo origin and identity of MSCs. That putative MSCs 
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have been isolated from many different vascularized tissues may be evidence of a 
perivascular origin (Caplan, 2008). A study by Crisan et al. characterized a population of 
perivascular cells in the microvasculatures of various tissues that displayed canonical 
MSC markers and tri-lineage differentiation capability, which implies that pericytes and 
MSCs are closely related, if not equivalent (Crisan, et al., 2008). It is possible that 
MSCs/pericytes play different physiological roles under different conditions. In stable 
adult tissues, these cells may function as pericytes, maintaining integrity and homeostasis 
in blood vessel walls. During early development or after tissue damage, the same cells 
might be induced to activate more MSC-associated functions , such as migration to an 
area and subsequent differentiation to a required cell type, deposition of extracellular 
matrix (ECM) components, or regulation/modulation of the behavior of other cells 
through the release of paracrine factors (Caplan, 2008). 
C3H/10Tl/2 Cells 
C3H/10Tl/2 cells are a clonal cell line derived from 14-17 day C3H mouse 
embryos by Reznikoff et al. (1973). Although the tissue of origin is unknown, lOTl/2 
cells display the characteristic marker expression and differentiation potential of typical 
mesenchymal stem cells. In vitro, they are plastic-adherent, sensitive to contact 
inhibition, and display a fibroblast-like morphology when subconfluent. In confluent 
cultures they take on a more rounded appearance, and cultures have a characteristic 
cobblestone appearance. Their genome is hypertetraploid for mice, with a chromosome 
number of 81 (normal diploid number is 40). They are non-tumorigenic when injected 
into mice, and do not express C-type retroviruses (Reznikoff et al., 1973; Pinney & 
Emerson, 1989). 
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C3H/10Tl/2 cells have been differentiated to several cell types: most commonly 
the three MSC hallmark lineages of adipocytes, chondrocytes, and osteocytes (Pinney & 
Emerson, 1989), but also to skeletal muscle (Kubo, 1991) and pericytes/smooth muscle 
cells (Proweller, Pear, & Parmacek, 2005). C3H/10Tl/2 cells express smooth 
muscle/pericyte markers, and have been used in coculture studies of angiogenesis to 
model mural cells (Ding, Darland, Parmacek, & D'Amore, 2004). Additionally, these 
cells have been reported to differentiate to endothelial cells induced by shear stress 
(Wang et al., 2005) or angiogenic factors (Wang et al., 2010) as induction stimuli. 
Effects of Angiogenic Factors on MSCs 
Basic fibroblast growthfactor. bFGF has been shown to stimulate proliferation in 
several cell types, including endothelial cells and MSCs (Martin, 1997; Tsutsumi, 2001; 
Ramasamy, et al. , 2012). In oligodendrocyte precursor cells, bFGF was found to 
stimulate proliferation by promoting cyclin D1 transcription by MAPK pathway 
activation, and by suppressing levels of p27, a CDK inhibitor (Frederick, Min, Altieri, 
Mitchell, & Wood, 2007; Frederick & Wood, 2004; Li & DiCicco-Bloom, 2004). c-Jun 
pathway activation by activated FGFR is important for cyclin D1 induction (Reilly & 
Maher, 2001). Several studies have found that MSCs do not lose their differentiation 
potential after bFGF-induced proliferation (Lee, 2012; Tsutsumi, 2001) and one study 
found that osteogenic differentiation was actually increased after bFGF-induced 
expansion compared with untreated controls (Martin, 1997), suggesting that bFGF may 
prime cells for subsequent differentiation. 
bFGF has also been shown to inhibit mural differentiation of MSCs. Papetti, 
Shujath, Riley, & Herman (2003) showed that TGF-~-mediated expression of SMC genes 
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in retinal pericytes is interrupted by treatment with bFGF. Another group found similar 
results in C3H/10Tl/2 cells, and reported that bFGF-mediated suppression of SMC genes 
was dependent on MEKIERK pathway activation (Kawai-Kowase, 2004). 
Aside from its effects on MSC proliferation and differentiation, bFGF can also 
control migration of MSCs. Schmidt et al. (2006) found that bFGF at low doses was 
attractant for bone marrow-derived MSCs, while at high doses MSCs were repelled. 
They also found that these behaviors were mediated through Akt/PKB pathway activation 
(Schmidt et al., 2006). 
Vascular endothelial growth factor. VEGF has been reported to induce 
endothelial differentiation of bone marrow MSCs (Oswald, 2004) and osteogenic 
differentiation of dental pulp MSCs (D'Alimonte et al., 2011). It has also been reported 
that VEGF in combination with bFGF can stimulate C3H/10Tl/2 cell endothelial 
differentiation (Wang et al., 2010). VEGF also stimulates proliferation in dental pulp 
MSCs (D'Alimonte et al., 2011) and bone marrow MSCs in a MEKIERK dependent 
manner (Kong et al. , 2010). Although MSCs do not express VEGF receptors (Wang et 
al., 2010; Ballet al., 2007), it has been shown that VEGF can stimulate PDGF receptors, 
which are expressed in MSCs (Ball et al., 2007). The contribution of the PDGF receptors 
to VEGF-mediated differentiation of MSCs is unknown. 
CHAPTER II 
OBJECTIVE AND SIGNIFICANCE 
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Mesenchymal stem cells have generated much excitement in the field of 
regenerative medicine. MSCs can differentiate to several lineages, and their tissue 
regenerative properties have been well-documented in animal models (Wakitani et al., 
1994; Wakitani et al., 2007). They can home to sites of injury, and not only differentiate 
into required cell types but can also promote restoration of injured tissues by production 
of microenvironmental components (Haynesworth, Baber, & Caplan, 1996) and the 
suppression of inflammation (Uccell et al., 2008). MSCs can be isolated from a wide 
variety of sources, and they are easily cultured and expanded in vitro, raising the 
possibility of autologous transplantation (the use of a patient's own stem cells to treat 
disease, reducing the risk of immune rejection). Although embryonic stem cells have a 
greater potential for differentiation than MSCs, ESCs are also harder to isolate and 
maintain in culture. Additionally, it has proven difficult to direct ESC differentiation to 
specific cell types and to obtain large quantities of pure ESC-derived cells, which makes 
MSCs an attractive alternative. Clarifying the potential for differentiation to various cell 
lineages and the mechanisms involved is necessary for establishing the generation of 
clinically useful MSC-derived cells. 
Because pathological angiogenesis is a contributing factor to a wide range of 
diseases, a great amount of effort has been devoted to understanding the mechanisms of 
this process. However, the contribution of MSCs to angiogenesis is still incompletely 
characterized. The similarities between putative MSCs and mural cells have been shown 
in detail, and it seems likely that MSCs can take part in angiogenesis by differentiating to 
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mural cell phenotypes. But a few studies indicate that MSCs also have the potential to 
become endothelial cells and incorporate into new vessel walls. Growth factor signaling 
is a major regulator of cell behavior during angiogenesis. The objective of this study is to 
clarify the effects of angiogenic growth factors on C3H/10Tl/2 cell differentiation to 
vascular cell types. Based on our preliminary observations of the individual effects of 
bFGF and VEGF, the current research proposes a more efficient method for the 
differentiation of C3H/10Tl/2 cells to an endothelial lineage than that used by Wang et 
al. (2010). Optimizing this method would potentially provide a new source for efficient 
generation of endothelial cells and a model for the study of endothelial induction, and 
could shed light on the participation of MSCs in the angiogenic process. 
CHAPTER III 
METHODS 
Mesenchymal Stem Cell Culture 
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The cells used in this study were C3HI10Tl/2 cells, described by Reznikoff et al. 
(1973). Cells were cultured in 10% FCS MEMa in a 37°C humidified incubator with 5% 
C02 atmosphere. For differentiation experiments, cells were seeded to 6-well culture 
dishes at low density ( -2000 cells/cm2) and growth factors (VEGF and bFGF, alone or in 
combination) were added to the medium at concentrations ranging from 5-10 ng/mL. 
Medium was refreshed every 3 days. 
HoxB5 Stable Transfection 
Cells were transfected with pcDNA3-HoxB5 plasmid using Lipofectamine 
(Invitrogen) transfection reagent. In a 1.5 mL microcentrifuge tube, 0.5 mL of Opti-
MEM (Invitrogen) and 5 )lg of pcDNA3 plasmid DNA were incubated for 5 minutes at 
room temperature. In another tube, 0.5 mL Opti-MEM and 20 J.!L Lipofectamine were 
also incubated for 5 minutes at room temperature. These two mixtures were combined 
and further incubated at room temperature for 25 minutes before being added to the cells. 
After 48 hours, G418 was added to the culture dish at 375 J..lg/mL to eliminate growth of 
untransfected cells. After two weeks, cells that survived were stably transfected, which 
was confirmed by RT-qPCR analysis for HoxB5. 
Spectrophotometric Analysis of Cell Number 
Treated C3H/10T1/2 cells were fixed with methanol for 15 minutes, then washed 
three times with PBS, followed by staining with toluidine blue (TB) for 30 minutes. 
Cells were rinsed with tap water to remove excess TB and allowed to air dry. The TB was 
extracted from the cells by a 2% SDS wash. Optical density was measured with a Bio-
Tek Instruments ELX 800 microplate reader and KCjunior software. 
RNA Extraction 
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Total RNA was extracted using Tri-reagent (Sigma). Medium was aspirated from 
the culture dish and Tri-reagent was added, followed by 3 minutes of shaking. The 
sample was transferred to a 1.5 mL microcentrifuge tube and stored at -70°C. Chloroform 
(0.2 mL per mL ofTri-reagent) was added, then samples were vortexed for 15 seconds 
and incubated at room temperature for 10 minutes. Next, samples were centrifuged at 
10000 rpm for 10 minutes at 4°C. The aqueous supernatant containing RNA was 
transferred to a new 1.5 mL microcentrifuge tube and an equal volume of isopropyl 
alcohol was added. After a 10 minute incubation at room temperature, samples were 
centrifuged at 12000 rpm for 15 minutes at 4°C to precipitate a pellet of RNA. The 
supernatant was aspirated and samples were washed with 0.7 mL cold 75% ethanol, 
vortexed, and placed in -20°C for at least one hour. Samples were then centrifuged at 
10000 rpm for 10 minutes at 4°C, ethanol was removed, and RNA pellets were allowed 
to dry for 5 minutes on ice. Finally, RNA was dissolved in 20 uL DEPC-water, RNA 
concentration was measured by a Spectronic Genesys 10 Bio spectrophotometer, and 
RNA integrity was checked by agarose gel electrophoresis. 
Reverse Transcription 
For each sample, 1 !lg of RNA was mixed with dNTPs and a random primer, 
mixed, and held at 70°C in a thermal cycler for 5 minutes to melt secondary structure 
within the RNA template. Then 5x buffer (Fisher), M-MLV reverse transcriptase 
(Fisher), RNase inhibitor (Fisher) were added for a total volume of 20 IlL per reaction 
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and samples were held at 42°C for a 1 hour extension step, followed by 10 minutes at 
95°C to inactivate the reverse transcriptase enzyme. Resulting eDNA was diluted in 200 
)..LL DEPC-water. 
Real-Time Semi-Quantitative Polymerase Chain Reaction (RT-qPCR) 
For each reaction, 10 )..LL of SYBR Green (Bio-Rad), 3 )..LL of nuclease-free water, 
and 5 )..LL of eDNA were mixed with 2 )..LL of gene-specific primers. Samples were run in 
a Stratagene MS3000P real-time PCR thermal cycler according to the protocol below 
(Table 1). Relative mRNA levels were calculated using the comparative Ct method 
(2AMC1). For all samples, P-actio was used as an internal reference control gene. 
Sequences of gene-specific primers are listed in Table 2. 
Table 1 
Cycling Protocol for RT-qPCR. 
Step Temperature and Duration N tunber of Cycles 
Denaturation 95°C for 3 minutes 1 cycle 
95°C for 15 seconds 
Amplification 60°C for 30 seconds 35 cycles 
72°C for 30 seconds 
95°C for 45 seconds 
Final extension 70°C for 30 seconds 1 cycle 
95°C for 30 seconds 
Table 2 
Sequences of Gene-specific Primers 
Gene 
~-actin 
aSMA 
SM22a 
PECAM1 
VE-cadherin 
VEGF-R2 
roouse HoxB5 
human HoxB5 
Accession 
Ntunber 
NM_008268 
NM_007392 
Forward Prirrer Reverse Prirrer 
CCTGCACTAACGGC TGGCCTCGTCTATTTCG 
GACAG GTGA 
GGACGTACAACTGG CGGCAGTAGTCACGAAG 
TATTGTGC GAAT 
NM_011526 AGGGATCGAAGCCA ACTGCTGCCATATCCTT 
GTGAAG ACCT 
NM_008816 TGCACCCATCACTT CTTCATCCACCGGGGCT 
ACCACC ATC 
NM_009868 ATGAATCGCTGCCC CATTCCCTGTGTTAGCA 
CACTATG TCGAC 
NM_010612 GCAAAACACTCACC GAGGTTTGAAATCGACC 
ATTCCCA CTCG 
NM_008268 CCTGCACTAACGGC TGGCCTCGTCTATTTCG 
GACAG GTGA 
NM_002147 TCCTCGGAGCCTGA CCCGTCCGGCCCGGTCA 
GGAAGCGGCAAG TATCATG 
Flow Cytometry Analysis of Cell Cycle and Protein Expression 
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Treated C3H/10Tl/2 cells were detached with trypsin, fixed with ethanol, blocked 
with 2% BSA, and incubated with primary antibody at 1:100 dilution for either 2 hat 
room temperature or overnight at 4 °C, followed by incubation with the secondary 
antibody at 1:200 dilution for 1 h in the dark. Propidium iodide (PI, a DNA binding dye) 
was added during the second antibody incubation for analysis of cell cycle profiles. 
Samples were then analyzed using an Accuri C6 flow cytometer and Cflow software. 
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CHAPTER IV 
RESULTS 
bFGF Stimulates Cell Proliferation 
As reported in other studies (Ramasamy et al., 2012; Tsutsumi, 2001), we found 
that treatment with bFGF stimulated proliferation of C3W10Tl/2 cells, as measured by 
three different methods. First, we used a spectrophotometer to measure the optical 
density of bFGF-treated and untreated cultures after staining with toluidine blue (Fig. 5). 
Increased optical density of the treated culture indicates a higher number of cells relative 
to untreated cells (Con). 
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Figure 5. Spectrophotometric analysis of cell proliferation. Cells were grown in 1% 
FBS MEM and treated with 10 ng/mL bFGF for 48h, then optical density was measured 
with a spectrophotometer after the cells were stained with TB. The values are means± 
SD (n = 3, P < 0.05). 
Next, we used flow cytometry to analyze the cell cycle profiles of treated and 
untreated cells (Fig. 6). By treating the cells with the DNA-binding fluorescent dye 
propidium iodide (PI), we measured the relative amounts of DNA in cells from treatment 
and control groups. Cells inS and G2/M phases of the cell cycle have a higher DNA 
content than cells in G 1 as they replicate their genomes in preparation for mitosis, and 
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thus will have higher fluorescence (farther to the right on the x-axis) as measured by flow 
cytometry. Figure 6 shows a higher proportion of cells in S and G2/M phases in the 
bFGF-treated group than in the control group, indicating increased proliferation in 
response to bFGF. 
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Figure 6. Cell cycle analysis by flow cytometry. Cells were treated with 10 ng/mL 
bFGF for 48h, then stained with propidium iodide, and flow cytometry was used to 
measure fluorescence as an indicator of DNA content. The cell populations at different 
phases of the cell cycle are indicated by bars. 
Finally, we measured the expression of cyclin Dl as an indicator of proliferation. 
Cyclin-dependent kinases (CDKs) and the cyclin proteins are major regulators that 
control cell cycle progression. CDKs and cyclins form complexes that phosphorylate 
numerous targets to allow progression through cell cycle checkpoints. While CDKs are 
relatively stably expressed, cyclins are only expressed at specific times in the cell cycle, 
which provides a mechanism to prevent uncontrolled cell growth. Thus, cyclin 
expression can serve as an indicator of active proliferation. As seen in figure 7, bFGF-
treated cells show increased cyclin D 1 mRNA levels relative to controls, which is 
responsible for the increased cell proliferation. 
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Figure 7. Analysis of cyclin D1 mRNA levels. Cells were treated with 10 ng/mL bFGF 
for 48h and collected for RT-qPCR. The values are means ± SD (n = 3, P < 0.05). 
bFGF Inhibits Mural Differentiation 
Consistent with other reports in the literature (Papetti et al., 2003; Kawai-Kowase, 
2004), we found that bFGF strongly inhibits transcription of the mural cell marker genes 
smooth muscle a-actin (SMA) and SM22u (Fig. 8). 
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Figure 8. Analysis of mural cell markers at mRNA level. Cells were treated with 10 
ng/mL bFGF for 72h and collected for RT-qPCR. The values are means ± SD (n = 3, P < 
0.01). 
We then used flow cytometry to verify the downregulation of SMA at the protein 
level. By incubating the cells with a primary antibody that binds to the SMA protein, and 
then incubating with a secondary antibody that binds the primary antibody and is 
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conjugated with a fluorophore (FITC), we fluorescently labeled the SMA protein in 
treated and untreated cells, then analyzed the intensity of fluorescence (which correlates 
with the expression level of SMA) in each group with a flow cytometer. As seen in 
figure 9, the bFGF-treated group had lower fluorescence than the control group (left-shift 
of bFGF-treated curve), confirming reduced expression of SMA at the protein level. 
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Figure 9. Analysis of SMA protein levels. Cells were treated with 10 ng/mL bFGF for 
48h, then fixed and incubated with SMA-specific antibodies and analyzed by flow 
cytometry. 
Next, we examined the expression of endothelial markers in response to bFGF 
treatment. Untreated C3H/10T1/2 cells have extremely low baseline expression levels of 
the endothelial markers PECAM-1 and VE-cadherin, and these levels were not 
significantly increased after 9 days of treatment with bFGF (Fig. 10). 
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Figure 10. Effects of bFGF on endothelial marker expression. Cells were treated with 5 
ng/mL bFGF for 9 days and collected for RT-qPCR. The values are means± SD (n = 3, P 
< 0.01). 
VEGF Treatment has no Significant Effects on Proliferation or Differentiation 
VEGF is a major growth factor regulator of angiogenesis, and has been reported 
to contribute to endothelial differentiation of MSCs in several studies (Oswald et al., 
2004; Wang et al., 2010). According to our results, treatment with VEGF alone did not 
cause any significant effects on proliferation (Fig. 11) or expression of mural or 
endothelial differentiation markers (Fig. 12). 
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Figure 11. Effects of VEGF on proliferation. Cells were grown in 1% FBS MEM and 
treated with 10 ng/mL VEGF for 48h, then optical density was measured with a 
spectrophotometer after the cells were stained with TB. The values are means± SD (n = 
3, p < 0.05). 
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Figure 12. Effects of VEGF on endothelial marker expression. Cells were treated with 
10 ng/mL VEGF for 9 days and collected for RT-qPCR. The values are means± SO (n = 
3, p < 0.01). 
Treatment with bFGF+ VEGF did not Stimulate Endothelial Differentiation 
Following the protocol of Wang et al. (2010), we treated C3H/10Tl/2 cells with a 
combination of bFGF and VEGF (5 ng/mL and 10 ng/mL, respectively) for 9 days. This 
treatment was reported to induce endothelial differentiation in this cell line, but our 
results show that the endothelial markers PECAM-1 and VE-cadherin are not 
significantly upregulated at the transcriptional (Fig. 13) or protein levels (not shown), and 
cells are morphologically similar to cells treated with bFGF alone (Fig. 14). 
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Figure 13. Effects of combined treatment with bFGF and VEGF on differentiation 
marker expression. Cells were treated with 5 ng/mL bFGF and 10 ng/mL VEGF for 9 
days and collected for RT-qPCR. The values are means± SO (n = 3, P < 0.01). 
30 
Figure 14. C3H/10Tl/2 cell morphology. Left panel, untreated cells. Middle panel, cells 
treated with 10 ng/mL bFGF for 3 days. Right panel, cells treated with 5 ng/mL bFGF 
and 10 ng/mL VEGF for 3 days . 
Because of the apparent low responsiveness to VEGF, we decided to examine the 
expression of Flld , the primary receptor for VEGF. In untreated cells, Flkl mRNA 
levels were neglible, and treatment with bFGF, VEGF, or a combination of both over a 9 
day course did not significantly increase Flkl transcription (Fig. 15) or protein levels 
(Fig. 16). 
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Figure 15. Effects of growth factor treatment on Flk1 expression. Cells were treated 
with 5 ng/mL bFGF, 10 ng/mL VEGF, or a combination of both for 9 days and collected 
for RT-qPCR. The values are means± SD (n = 3, P < 0.01). 
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Figure 16. Analysis of Flk1 protein levels. Cells were treated with 10 ng/mL VEGF (red 
curve) or left untreated (black curve) for 9 days, then fixed and incubated with Flk1-
specific antibodies and analyzed by flow cytometry. 
HoxB5 Transfection did not Induce Flk1 Expression or Endothelial Differentiation 
In order to promote endothelial differentiation, we attempted to induce expression 
of Flk1 so that cells would be more responsive to VEGF. Toward this end, we 
transfected C3H cells with HoxB5, a transcription factor that has been shown to bind to 
an intronic enhancer region of the Flk1 gene and increase endothelial differentiation in 
HoxB5-transfected embryonic stem cells (Wu, Moser, Bautch, & Patterson, 2003). 
Although transfection was successful and HoxB5 was expressed at high levels, we did 
not observe a significant increase in Flk1 transcription (Fig. 17). HoxB5 transfected cells 
did show some upregulation of endothelial markers after growth factor treatment, but the 
increases were not statistically significant and absolute expression levels remained 
extremely low (Fig. 18). 
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Figure 17. HoxB5 and Flk1 expression in na"ive and HoxB5-transfected cells. Inset: RT-
PCR result after gel electrophoresis. (-) and ( +) represent untransfected and transfected 
cells, respectively. 
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Figure 18. Effects of growth factor treatment on HoxB5-transfected cells. Cells were 
treated with 5 ng/mL bFGF, 10 ng/mL VEGF, or a combination of both for 9 days, then 
collected for RT-qPCR. The values are means± SD (n = 3, P < 0.01). 
Finally, to verify that the HoxB5 gene we transfected was functional, we 
transfected D3 embryonic stem cells and analyzed expression of HoxB5 and endothelial 
markers. As seen in Figure 19, HoxB5 transfection resulted in increased transcription of 
Flk1 , which is consistent other reports (Wu et al. , 2003). 
0 .007 -,----------------l 
c 
ts 0 .006 
ca 
I 
co 0 .005 -1------l! 
0 
... 
QJ 
.2: 0.004 +------1, 
... 
ca 
~.00015 +----·.-. 
c 
0 
·~ 0.0001 +----
QJ 
.. 
~.00005 
L&J 
0 
HoxBS Flkl 
HoxBS 
Flkl 
+ 
. 03 
• Ho.xBS-03 
Figure 19. HoxB5 and Flkl expression in na"ive and HoxB5-transfected D3 embryonic 
stem cells. Inset: RT -PCR result after gel electrophoresis. (-) and (+)represent 
untransfected and transfected cells, respectively. 
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CHAPTER V 
DISCUSSION 
34 
The differentiation capacity of mesenchymal stem cells has not been fully 
elucidated. MSCs classically give rise to cartilage, fat, and bone-producing cells, but 
have also reportedly been differentiated to smooth and cardiac muscle cells, neurons, and 
endothelial cells (Pinney & Emerson, 1989; Minguell et al. Conget, 2010; Wang et al., 
2010; Woodbury et al., 2000; Oswald et al. 2004). Endothelial cells typically develop 
from an early precursor cell type called a hemangioblast, which gives rise to blood cells 
as well as endothelial progenitor cells (Ferguson, Kelley, & Patterson, 2005). Although 
the ontogeny of MSCs remains unclear, they are distinct from both hematopoietic stem 
cells and endothelial progenitor cells, so reports of MSC differentiation to ECs deserve 
further attention and clarification. 
Several papers report in vivo differentiation of MSCs to ECs (Davani, et al., 2003; 
Tang, et al., 2006), usually involving injection of DAPI-labeled MSCs into infarcted 
cardiac tissue, then performing immunohistochemistry to characterize the phenotype of 
labeled cells after several days or weeks. However, this experimental design does not 
allow analysis of the molecular mechanisms that lead to endothelial differentiation. 
There are a few reports of endothelial induction in vitro, including two that used the 
C3W10Tl/2 cell line (Wang et al., 2005; Wang et al., 2010). One study used shear stress 
as an induction stimulus (Wang et al., 2005). This result is not surprising, as shear forces 
have been shown to have strong effects on cell morphology, gene expression, and 
differentiation of endothelial progenitor cells (Yamamoto et al., 2003). Two studies 
reported endothelial induction after treatment with angiogenic growth factors. Oswald et 
al. (2004) reported that human bone marrow-derived MSCs could be differentiated to 
endothelial cells after treatment with high doses of VEGF, and Wang et al. (2010) 
reported endothelial induction of C3H/10Tl/2 cells using a combination of bFGF and 
VEGF. In the present study, we attempted to validate and expand on these reports by 
analyzing the effects of individual angiogenic factors on differentiation to vascular cell 
types. 
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We found that the two major effects of bFGF were to stimulate proliferation and 
to inhibit mural differentiation markers such as a-SMA and SM22a. These effects have 
been previously reported in C3H cells and other MSCs (Papetti et al. 2003; Kawai-
Kowase, 2004), and are consistent with a role for bFGF as an inhibitor of mural 
differentiation. The endothelial markers PECAM-1 and VE-cadherin are not expressed 
in untreated C3H cells, and bFGF did not induce significant transcription of these genes. 
Although VEGF is a major regulator of vascular development, and is used as a 
stimulus in almost all reports of endothelial differentiation of MSCs, we did not observe 
any significant effects on proliferation or transcription of mural or endothelial 
differentiation markers after 9 days of stimulation with VEGF. Because naive 
C3H/10Tl/2 cells express mural cell markers at relatively high levels-indeed, these 
cells are often used as de facto mural cells in coculture with endothelial cells for 
modeling angiogenesis-it is possible that VEGF is not able to easily overcome this 
inherent mural character. It was thought that the addition of bFGF to the protocol to 
inhibit mural cell markers and de-differentiate the cells might enhance VEGF-induced 
endothelial induction. Following the protocol of Wang et al. (2010), we treated cells with 
a combination of 5 ng/mL bFGF and 10 ng/mL VEGF for 9 days. The effects were 
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similar to treatment with bFGF alone: increased proliferation and decreased transcription 
of mural cell makers, with no induction of endothelial markers. Because the effects of 
bFGF seemed to predominate when both factors were used simultaneously, we also tried 
a step-wise treatment method, in which cells were pre-treated with bFGF for 48h before 
treatment with VEGF or a VEGF+bFGF combination, but we obtained results similar to 
those of simultaneous treatment (data not shown). 
The apparent inablility of these cells to respond to VEGF could be attributable to 
the lack of expression of Flkl (a.k.a. VEGFR2), the major cell surface receptor for 
VEGF. Despite the use of VEGF in many studies on MSCs, most published expression 
profiles show that MSCs, including C3H/10Tl/2 cells, do not express VEGF receptors. 
One paper reports that VEGF can bind to and activate the surface receptor for the closely 
related platelet-derived growth factor (PDGF), which is expressed in MSCs (Ballet al., 
2007); however, the intracellular effects of this activation would presumably be identical 
to those of PDGF, which is not involved in endothelial differentiation. 
To determine whether Flk1 is in fact the missing link in the capacity for 
endothelial differentiation of C3H cells, we attempted to induce Flk1 by expressing the 
transcription factor HoxB5. This protein has been reported to bind to an intronic 
enhancer region of the Flk1 gene and increase Flk1 expression in embryonic stem cells 
(Wu et al. 2003). Although we successfully transfected the cells with HoxB5 (Fig. 17), 
we did not observe any increase in Flk1 transcription after real-time PCR analysis. 
However, when PCR products were were subjected to gel electrophoresis, a very faint 
band of the expected size for Flk1 amplicons was visible in transfected cells (Fig. 17, 
inset), indicating that some low-level induction did occur. It may be that the Flk1 gene in 
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C3H/10Tl/2 cells is mostly unavailable for HoxB5 binding (or binding of other necessary 
transcription factors) due to epigenetic modifications such as DNA methylation or 
histone modifications. Consistent with this theory, we found that HoxB5 did increase 
Flkl transcription in D3 ESCs, which are undifferentiated and thus should not be 
epigenetically restricted in terms of differentiation capacity. Cell reprogramming 
methods, such as those used to generate iPSCs (Takahashi & Yamanaka, 2006), generally 
involve the use of master regulatory transcription factors that reset genome-wide DNA 
methylation patterns, causing a reversion to an undifferentiated state. In this case, it 
seems that the change from MSC to endothelial lineage may be too drastic to be induced 
by our methods. 
In conclusion, our results indicate that C3H/10Tl/2 cells do not differentiate to 
endothelial cells in vitro in response to two prototypical angiogenic factors. It seems that 
this cell line is intrinsically closer to a mural cell phenotye. Simple stimulation with 
bFGF and VEGF is unable to cause transdifferentiation to the endothelial lineage, even in 
the cells expressing HoxB5, which upregulates Flkl in embryonic stem cells. While 
C3H/10T 112 cells theoretically have the potential to differentiate into endothelial cells, 
that will need a more rigorous reprogramming strategy that involves manipulating 
multiple transcription factors driving endothelial cell differentiation. 
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